Core Points - Jiangxi Fushine Pharmaceutical Co., Ltd. aims to maximize shareholder value while providing safe and effective pharmaceutical products globally [3][4] - The company was established on August 29, 2012, and registered with a capital of RMB 538,648,934 [3][4] - The company operates as a public limited company and is governed by its articles of association, which are legally binding [2][3] Company Structure - The company is a permanent public limited company, with the chairman acting as the legal representative [2][3] - Shareholders are liable only to the extent of their subscribed shares, while the company is responsible for its debts with its total assets [2][3] - The articles of association provide a framework for the rights and obligations of shareholders, directors, and senior management [2][3] Business Objectives and Scope - The company's business objective is to maximize shareholder interests and innovate in the pharmaceutical sector [3][4] - The business scope includes the production and import/export of pharmaceuticals and hazardous chemicals, among other activities [3][4] Share Issuance and Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [4][5] - The total number of shares issued is 538,648,934, all of which are ordinary shares [4][5] - The company cannot provide financial assistance for others to acquire its shares, except under specific conditions [5][6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company governance [9][10] - Shareholders must comply with laws and the articles of association, and they cannot withdraw their capital except as legally permitted [14][15] - The articles outline the responsibilities of controlling shareholders and actual controllers to protect the interests of the company and other shareholders [14][15] Shareholder Meetings - The company holds annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [47][48] - Shareholder proposals must be submitted in advance, and the company must provide adequate notice of meetings [57][58] - The articles specify the voting procedures and requirements for decision-making during shareholder meetings [63][64]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开第四 届董事会第二十八次会议，审议通过了《关于修订 <公司章程> 及制定、修改部分管理 制度的议案》。根据《公司法》《上市公司章程指引》等有关法律法规的规定和要求， 并结合公司实际情况，公司决定修订《公司章程》及制定、修改部分管理制度，具体 内容如下： 一、修订《公司章程》情况 鉴于公司拟将回购账户中 11,355,900 股用途由"用于实施员工持股计划或股权激 励"变更为"用于注销并减少注册资本"。本次股份注销和减资完成后，公司总股本 减少 11,355,900 股，公司总股本将由 550,004,834 股变更为 538,648,934 股。注册资本 由人民币 550,004,834 元变更为人民币 538,648,934 元。同时，根据《公司法》《上市 公司章程指引》《上市公司信息披露管理办法》等有关法律法规及规范性文件的最新 修订和更新情况，公司修订《江西富祥药业股份有限公司章程》，其中公司拟调整三 会结构，将不再设置监事会 ...

Core Points - The document outlines the operational guidelines and management structure of Jiangxi Fuxiang Pharmaceutical Co., Ltd, emphasizing the need for institutionalization, standardization, and scientific management to ensure sound decision-making [2][3] Group 1: General Provisions - The company aims to adapt to modern corporate governance requirements and ensure the correctness and rationality of major business decisions [2] - The General Manager is responsible for daily operations under the Board of Directors' leadership and must execute board resolutions [2] Group 2: Appointment of General Manager - The General Manager and Board Secretary are nominated by the Chairman and appointed by the Board of Directors, while other senior management is nominated by the General Manager [3] - The General Manager's term is three years, with the possibility of reappointment [3] Group 3: Powers and Responsibilities of the General Manager - The General Manager has the authority to manage daily operations, implement annual plans, and propose internal management structures [5][6] - In emergencies, the General Manager can make temporary decisions outside their usual authority but must report to the Board afterward [5] Group 4: Responsibilities of the Deputy General Manager - The Deputy General Manager assists the General Manager and is responsible for their designated duties, reporting regularly to the General Manager [7] Group 5: Financial Responsibilities - The company appoints a Financial Officer responsible for managing financial activities and ensuring compliance with financial regulations [9] - The Financial Officer must report to the General Manager and participate in major financial decision-making [9] Group 6: Dismissal of the General Manager - The Board of Directors must dismiss the General Manager under specific circumstances, such as the end of the term or failure to meet appointment conditions [10][11] - The General Manager cannot resign without prior approval from the Board, especially in critical situations [11][12]

Core Viewpoint - The company has established a system to enhance the accountability of annual report information disclosure, aiming to improve the quality and transparency of financial reporting and ensure compliance with relevant laws and regulations [1][2][3]. Group 1: Accountability and Responsibility - The system applies to all personnel involved in the annual report disclosure process, including major shareholders, directors, senior management, and relevant staff, holding them accountable for significant economic losses or negative social impacts caused by non-compliance [1][2]. - The company emphasizes strict adherence to the "Enterprise Accounting Standards" and internal control systems to ensure that financial reports accurately reflect the company's financial status, operational results, and cash flows [2][3]. Group 2: Identification of Major Errors - Major errors in annual report disclosures include significant accounting errors in financial reports, substantial discrepancies in performance forecasts, and other significant omissions or errors in disclosures [2][3][4]. - Specific criteria for identifying major accounting errors include discrepancies exceeding 5% of total audited assets, net assets, revenues, or net profits, with absolute amounts exceeding 5 million [4][5]. Group 3: Correction and Audit Procedures - When significant errors are identified, the company must engage a qualified accounting firm to audit the corrected financial reports [5][6]. - The internal audit department is responsible for collecting relevant information, investigating causes, and proposing corrective measures, which must be reviewed by the board of directors [5][6]. Group 4: Consequences of Major Errors - The company will pursue accountability for individuals responsible for significant errors in annual report disclosures, including the chairman, general manager, and financial officers, who bear primary responsibility for the accuracy and completeness of financial reports [6][7]. - Penalties for responsible individuals may include internal criticism, warnings, demotions, or even termination of employment, depending on the severity of the error [7][8].

Group 1 - The Shanghai Composite Index has recently surpassed the annual high set on March 18, 2025, and is approaching the high from October 8, 2024, indicating a significant market movement [1] - There is a noticeable divergence among various sectors, with banking, agriculture, personal care, military, chemical, transportation, and petrochemical industries showing a higher proportion of stocks exceeding their March 18, 2025 closing prices [1] - Conversely, sectors such as steel, electronics, home appliances, telecommunications, computers, and electrical equipment have a lower proportion of stocks exceeding their March 18, 2025 levels [1] Group 2 - In the secondary industry analysis, financial (banking, insurance, diversified finance), military (naval equipment, ground weaponry), agriculture (animal health, agricultural products, planting, feed), precious metals, personal care products, and chemical pharmaceuticals show a higher proportion of stocks exceeding their March 18, 2025 closing prices [4] - Sectors like home appliances, electrical equipment, TMT (television broadcasting, communication services, consumer electronics, semiconductors, optical electronics), general steel, and machinery (engineering machinery, automation equipment) have a lower proportion of stocks exceeding their March 18, 2025 levels [4] - Comparing to the October 8, 2024 closing prices, banking, motorcycles, military (ground weaponry, aerospace equipment), chemicals (plastics, non-metallic materials), and new consumption (entertainment products, personal care products, retail, accessories) show a higher proportion of stocks exceeding their previous levels [4]

Core Viewpoint - The company has successfully obtained GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for four chemical raw materials, indicating compliance with international quality standards [1] Group 1: Certification Details - The GMP certification was conducted from March 17 to March 21, 2025, covering the following products: Candesartan Cilexetil, Sacubitril/Valsartan, Telmisartan, and Valsartan [1] - The certification is valid until May 26, 2027, and June 9, 2027, respectively, for the two certificates issued by ANVISA [1] - The on-site inspection by ANVISA concluded that the company’s facilities met the required standards, resulting in a qualified status for the four raw material products [1]

Group 1 - The stock of Yuandong Biotech (688513) has a comprehensive score of 51.09, indicating a strong performance [1] - The current main cost is 40.70 CNY, with a 5-day main cost of 39.96 CNY, a 20-day main cost of 41.49 CNY, and a 60-day main cost of 36.93 CNY [1][2] - The stock has not experienced any limit-up or limit-down events in the past year [1] Group 2 - The stock price has broken through the short-term resistance level, suggesting a potential short-term strength, while the mid-term trend remains unclear [2] - The net inflow of main funds on June 27, 2025, was 13.76 million CNY, accounting for 7% of the total transaction volume [2] - The financial data shows earnings per share of 0.34 CNY, operating profit of 0.62 billion CNY, and a sales gross margin of 79.155% [3][2] Group 3 - The stock is associated with several industry sectors, including chemical pharmaceuticals (0.94%), infant and child concepts (0.71%), monoclonal antibodies (0.72%), and immunotherapy (1.10%) [4]

Market Overview - The FTSE China A50 Index components showed a significant decline, with many stocks closing in the red, particularly in the banking sector [1][5]. Insurance Sector - China Pacific Insurance had a market capitalization of 387.40 billion, with a trading volume of 1.207 billion, experiencing a decrease of 0.68 (-1.81%) [3]. - China Life Insurance had a market capitalization of 355.57 billion, with a trading volume of 3.833 billion, down by 0.62 (-1.08%) [3]. - Ping An Insurance reported a market capitalization of 1,037.26 billion, with a trading volume of 10.68 billion, declining by 0.24 (-2.67%) [3]. Alcohol Industry - Kweichow Moutai had a market capitalization of 1,762.56 billion, with a trading volume of 54.04 billion, down by 3.19 (-1.78%) [3]. - Wuliangye Yibin reported a market capitalization of 215.28 billion, with a trading volume of 19.14 billion, decreasing by 0.55 (-0.46%) [3]. - Shanxi Fenjiu had a market capitalization of 462.61 billion, with a trading volume of 9.74 billion, down by 16.91 (-1.19%) [3]. Semiconductor Sector - Northern Huachuang had a market capitalization of 232.26 billion, with a trading volume of 17.24 billion, decreasing by 3.40 (-0.78%) [3]. - Cambricon Technologies reported a market capitalization of 244.42 billion, with a trading volume of 48.08 billion, down by 25.00 (-4.10%) [3]. - Haiguang Information had a market capitalization of 323.08 billion, with a trading volume of 23.89 billion, declining by 2.75 (-1.94%) [3]. Automotive Sector - BYD had a market capitalization of 282.79 billion, with a trading volume of 46.33 billion, down by 3.20 (-0.95%) [3]. - Great Wall Motors reported a market capitalization of 1,836.54 billion, with a trading volume of 3.08 billion, remaining unchanged [3]. - Beijing-Shanghai High-Speed Railway had a market capitalization of 182.56 billion, with a trading volume of 6.01 billion, down by 0.07 (-1.20%) [3]. Oil and Shipping Sector - China COSCO Shipping had a market capitalization of 686.25 billion, with a trading volume of 7.22 billion, down by 0.12 (-1.37%) [3]. - Sinopec reported a market capitalization of 1,577.64 billion, with a trading volume of 10.47 billion, increasing by 0.04 (+0.27%) [3]. - China National Petroleum Corporation had a market capitalization of 232.97 billion, with a trading volume of 8.30 billion, down by 0.05 (-0.88%) [3]. Coal Industry - China Shenhua Energy had a market capitalization of 793.35 billion, with a trading volume of 59.85 billion, down by 0.11 (-0.27%) [3]. - Shaanxi Coal and Chemical Industry reported a market capitalization of 187.11 billion, with a trading volume of 9.74 billion, down by 1.80 (-0.71%) [3]. - Contemporary Amperex Technology Co., Ltd. (CATL) had a market capitalization of 1,144.34 billion, with a trading volume of 7.75 billion, increasing by 0.23 (+1.21%) [3]. Other Sectors - China Nuclear Power had a market capitalization of 192.10 billion, with a trading volume of 4.50 billion, down by 0.89 (-2.86%) [4]. - Yangtze Power reported a market capitalization of 739.43 billion, with a trading volume of 6.81 billion, down by 0.04 (-0.43%) [4]. - Dongfang Fortune had a market capitalization of 364.13 billion, with a trading volume of 194.29 billion, down by 0.09 (-0.39%) [4].

Core Viewpoint - The FTSE China A50 Index components showed a decline across various sectors, with banking stocks mostly in the red and significant drops in insurance, liquor, and semiconductor sectors [1][6]. Banking Sector - Most banking stocks experienced a decline, contributing to the overall negative performance of the index [1]. Insurance Sector - Major insurance companies like China Pacific Insurance, Ping An Insurance, and China Life Insurance saw market capitalizations of 390.94 billion, 359.61 billion, and 1,045.27 billion respectively, with declines of -0.26 (-0.69%), -0.18 (-0.31%), and -0.16 (-1.78%) [3]. Liquor Industry - Key players in the liquor industry, including Kweichow Moutai, Shanxi Fenjiu, and Wuliangye, reported market capitalizations of 1,778.15 billion, 217.75 billion, and 464.59 billion respectively, with price changes of -4.50 (-0.32%), -1.16 (-0.65%), and -0.04 (-0.03%) [3]. Semiconductor Sector - Semiconductor companies such as Northern Huachuang, Cambricon Technologies, and Hygon reported market capitalizations of 233.53 billion, 249.53 billion, and 326.76 billion respectively, with price changes of -1.01 (-0.23%), -12.76 (-2.09%), and -1.17 (-0.83%) [3]. Automotive Sector - In the automotive sector, BYD and Great Wall Motors had market capitalizations of 282.79 billion and 1,834.50 billion respectively, with price changes of -3.57 (-1.06%) and +0.07 (+0.33%) [3]. Energy Sector - Companies in the energy sector, including China Shipping and Sinopec, reported market capitalizations of 686.25 billion and 1,584.96 billion respectively, with price changes of +0.03 (+0.20%) and -0.05 (-0.88%) [3]. Coal Industry - In the coal industry, China Shenhua and Shaanxi Coal and Chemical Industry had market capitalizations of 186.24 billion and 795.34 billion respectively, with price changes of -1.98 (-0.78%) and -0.01 (-0.02%) [3]. Power Industry - The power sector, represented by companies like Yangtze Power and China Nuclear Power, had market capitalizations of 192.31 billion and 745.30 billion respectively, with price changes of -0.65 (-2.09%) and -0.03 (-0.32%) [4]. Internet Services - Internet service companies such as Dongfang Caifu reported a market capitalization of 371.40 billion, with a price change of +0.37 (+1.60%) [4]. Food and Beverage Sector - In the food and beverage sector, companies like Citic Securities and Haitian Flavoring reported market capitalizations of 414.23 billion and 342.55 billion respectively, with price changes of +0.38 (+1.38%) and -0.10 (-0.26%) [4]. Consumer Electronics - Companies in the consumer electronics sector, including Industrial Fulian and Luxshare Precision, had market capitalizations of 426.17 billion and 246.39 billion respectively, with price changes of +0.42 (+2.00%) and -0.35 (-0.67%) [4]. Home Appliances - In the home appliance sector, Gree Electric and Haier Smart Home reported market capitalizations of 255.76 billion and 234.57 billion respectively, with price changes of +0.16 (+0.35%) and +0.28 (+1.13%) [4]. Logistics Sector - The logistics sector, represented by companies like SF Holding, had a market capitalization of 276.36 billion, with a price change of +0.60 (+1.13%) [4]. Construction Industry - In the construction industry, China State Construction and XD China Communications reported market capitalizations of 240.07 billion and 527.30 billion respectively, with price changes of -0.02 (-0.34%) and +0.05 (+0.95%) [4].

东莞证券认为，周四，市场三大指数集体回调。从技术分析角度看，沪指依然位于5日均线上方，技术 形态上显示企稳向上的态势。当前，随着稳增长政策持续发力，基建投资稳步推进、消费刺激政策成效 显现，宏观经济企稳回升的趋势进一步明朗。另一方面，维护资本市场平稳运行已成为政策目标之一， 政策性资金托底意愿增强，叠加流动性合理充裕，市场出现系统性大幅调整的可能性相对较低。在海外 主要经济体降息预期升温、国内经济基本面延续稳定以及市场风险偏好有所修复的多重因素共同作用 下，A股短期或仍显韧性。7月中报披露窗口临近，基本面信号将成为市场关注焦点，预计A股市场将呈 现震荡修复格局。 渤海证券认为，A股当前估值总体适中，流动性增量预期较强，令估值端有明显的支撑。因此，下半年 A股市场将延续下有底的特征，在增量流动性的推动下，市场将有较强的结构性空间，指数也将随着外 部风险的化解和成交的活跃，而具备震荡上行的条件。 中原证券认为，周四早盘股指低开后震荡上扬，盘中沪指在3461点附近遭遇阻力，午后股指维持震荡， 盘中通信设备、文化传媒、旅游酒店以及电子元件等行业表现较好；化学制药、半导体、美容护理以及 生物制品等行业表现较弱。长期资金 ...